Claims
- 1. An aqueous suspension with excellent redispersibility which comprises a hardly soluble steroidal antiinflammatory agent together with a water-soluble polymer, whereina) the water-soluble polymer is at least one member selected from the group consisting of hydroxypropylmethyl cellulose, methylcellulose, hydroxyethylcellulose, hydroxypropylcellulose, polyvinylpyrrolidone and polyvinyl alcohol, b) a concentration of the water-soluble polymer is within a range of 0.0001 to less than 0.01% (w/v), c) a ratio of the water-soluble polymer to the hardly soluble steroidal antiinflammatory agent is 0.0005 to 0.1 part by weight of the former to 1 part by weight of the latter, and d) said aqueous suspension when redispersed is a uniform suspension without aggregation of suspended particles.
- 2. The aqueous suspension of claim 1, wherein the water-soluble polymer is at least one member selected from the group consisting of hydroxypropylmethyl cellulose, methylcellulose, hydroxyethylcellulose and hydroxypropylcellulose.
- 3. The aqueous suspension of claim 1, wherein the water-soluble polymer is hydroxypropylmethyl cellulose or methylcellulose.
- 4. The aqueous suspension of claim 1, wherein the water-soluble polymer is polyvinylpyrrolidone or polyvinyl alcohol.
- 5. The aqueous suspension of claim 1, wherein the steroidal antiinflammatory agent is at least one member selected from the group consisting of cortisone acetate, hydrocortisone acetate, betamethasone, prednisolone, fluiticasone propionate, dexamethasone, triamcinolone, loteprednol, fluorometholone, difluprednate, momethasone furoate, clobetasol propionate, diflorasone diacetate, diflucortolone valerate, fluocinonide, amcinonide, halcinonide, fluocinolone acetonide, triamcinolone acetonide, flumetasone pivalate and clobetasone butyrate.
- 6. The aqueous suspension of claim 5, wherein the steroidal antiinflammatory agent is fluorometholone.
- 7. The aqueous suspension of claim 1, wherein said suspension is a topical ophthalmic preparation.
- 8. The aqueous suspension of claim 1, wherein said suspension is a topical nasal preparation.
- 9. An ophthalmic aqueous suspension with excellent redispersibility which comprises fluorometholone and 0.0001 to less than 0.01% (w/v) of hydroxypropylmethyl cellulose, wherein the ratio of hydroxypropylmethyl cellulose to fluorometholone is 0.0005 to 0.1 part by weight of the former to 1 part by weight of the latter.
- 10. An ophthalmic aqueous suspension with excellent redispersibility which comprises fluorometholone and 0.0001 to less than 0.01% (w/v) of methylcellulose, wherein the ratio of methylcellulose to fluorometholone is 0.0005 to 0.1 part by weight of the former to 1 part by weight of the latter.
Priority Claims (1)
Number |
Date |
Country |
Kind |
09-124166 |
May 1997 |
JP |
|
Parent Case Info
This application is a division of application Ser. No. 09/873,348, filed Jun. 5, 2001, now U.S. Pat. No. 6,448,296, issued Sep. 10, 2002, which is a division of application Ser. No. 09/423,558 filed Nov. 10, 1999, now U.S. Pat. No. 6,274,634, issued Aug. 14, 2001, which is a 371 of PCT/JP98/01998, filed Apr. 30, 1998.
US Referenced Citations (11)
Foreign Referenced Citations (11)
Number |
Date |
Country |
0 531 529 |
Feb 1993 |
EP |
0531529 |
Mar 1993 |
EP |
0 709 099 |
May 1996 |
EP |
52-96721 |
Aug 1977 |
JP |
60-161915 |
Aug 1985 |
JP |
3-135924 |
Jun 1991 |
JP |
4-288013 |
Oct 1992 |
JP |
5-186348 |
Jul 1993 |
JP |
8-151332 |
Jun 1996 |
JP |
8-295622 |
Nov 1996 |
JP |
9937286 |
Jul 1999 |
WO |